PATENT CLAIM ANALYSIS

Application Number: 16025835
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "100000"]

Abstract:
Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.

Claim (Index 1):
A method of treating a human subject having Burkitt's lymphoma, comprising:\n (i) determining if said lymphoma expresses an N-myristoyltransferase 1 (NMT1) protein; (ii) determining if said lymphoma comprises epigenetic inactivation of an N-myristoyltransferase 2 (NMT2) gene or loss of protein function or having a level of NMT2 protein that is low or absent compared to a control level of NMT2 protein expressed by normal human B cells; and if (i) and (ii) are true, administering to said human subject a therapeutically effective amount of an inhibitor of NMT1 protein, wherein said NMT1 inhibitor inhibits NMT1 protein activity.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.6087
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13971662', '14817754', '15257478', '14201184', '10699874']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6887808765642078
- 35 USC 102 Novelty (BERT): 0.4980158631684377
- Combined Prediction Score: 0.6697043752246308
- Mean Citation Score: 182.044068
- Max Citation Score: 196.92145
- Similarity Product: 134.54128910207152

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test